Related Experiment Video
Updated: Aug 30, 2026

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for
Vinay Tergaonkar1, Virginie Bottero, Masahito Ikawa
1Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.
Abstract:
Antiapoptotic activity of NF-kappaB in tumors contributes to acquisition of resistance to chemotherapy. Degradation of IkappaB is a seminal step in activation of NF-kappaB. The IkappaB kinases, IKK1 and IKK2, have been implicated in both IkappaB degradation and subsequent modifications of NFkappaB. Using mouse embryo fibroblasts (MEFs) devoid of both IKK1 and IKK2 genes (IKK1/2(-/-)), we document a novel IkappaB degradation mechanism. We show that this degradation induced by a chemotherapeutic agent, doxorubicin (DoxR), does not require the classical serine 32 and 36 phosphorylation or the PEST domain of IkappaBalpha. Degradation of IkappaBalpha is partially blocked by phosphatidylinositol 3-kinase inhibitor LY294002 and is mediated by the proteasome. Free NF-kappaB generated by DoxR-induced IkappaB degradation in IKK1/2(-/-) cells is able to activate chromatin based NF-kappaB reporter gene and expression of the endogenous target gene, IkappaBalpha. These results also imply that modification of NF-kappaB by IKK1 or IKK2 either prior or subsequent to its release from IkappaB is not essential for NF-kappaB-mediated gene expression at least in response to DNA damage. In addition, DoxR-induced cell death in IKK1/2(-/-) MEFs is enhanced by simultaneous inhibition of NF-kappaB activation by blocking the proteasome activity. These results reveal an additional pathway of activating NF-kappaB during the course of anticancer therapy and provide a mechanistic basis for the observation that proteasome inhibitors could be used as adjuvants in chemotherapy.
Insights
This study reveals a new way chemotherapy drug doxorubicin activates NF-kappaB in cancer cells lacking IKK1/2. Blocking proteasome activity enhances chemotherapy effectiveness by inhibiting this NF-kappaB activation pathway.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Nuclear factor kappa B (NF-kappaB) promotes tumor survival and chemotherapy resistance.
- NF-kappaB activation involves the degradation of its inhibitor, IkappaB.
- IKappaB kinases (IKK1 and IKK2) are traditionally linked to IkappaB degradation.
Purpose of the Study:
- To investigate a novel IkappaB degradation mechanism independent of IKK1/2.
- To explore the role of this pathway in chemotherapy resistance.
- To identify potential therapeutic targets for enhancing anticancer treatments.
Main Methods:
- Utilized IKK1/2-deficient mouse embryo fibroblasts (MEFs).
- Administered doxorubicin (DoxR) to induce IkappaB degradation.
- Assessed IkappaBalpha degradation, NF-kappaB reporter gene activity, and endogenous gene expression.
- Investigated the role of phosphatidylinositol 3-kinase (PI3K) and proteasome inhibition.
Main Results:
- Doxorubicin induced IkappaBalpha degradation in IKK1/2(-/-) MEFs via a non-classical pathway, independent of serine 32/36 phosphorylation and the PEST domain.
- This degradation was partially blocked by the PI3K inhibitor LY294002 and mediated by the proteasome.
- Activated NF-kappaB in these cells could still induce target gene expression.
- Combined doxorubicin treatment and proteasome inhibition significantly enhanced cell death in IKK1/2(-/-) MEFs.
Conclusions:
- A novel, IKK1/2-independent pathway for NF-kappaB activation exists, triggered by DNA damage.
- NF-kappaB modification by IKK1/2 is not essential for gene expression following DNA damage.
- Proteasome inhibitors can serve as effective adjuvants in chemotherapy by targeting this alternative NF-kappaB activation route.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity
MAPK Signaling Cascades
Abnormal Proliferation

